News

The decreased loss was primarily attributable to a $7.4 million decrease in R&D costs, the recognition in the 2008 period of the $5.94 million non-refundable license fee received

Revenue for the fiscal third quarter of 2009 was $75.31 million, an increase of 12%, compared to $67.03 million for the prior-year period. For the first nine months

According to Mayer Laboratories, the Today Sponge affords the freedom and flexibility of 24-hour contraceptive protection, and offers a safe and effective non-hormonal birth control alternative for women.

The company has appointed Ugo DeBlasi as its new CFO. In this position, Mr DeBlasi will provide leadership to the Celera finance, investor relations and information technology function,

On March 30, 2009, the FDA granted approval for a generic version of AstraZeneca’s Pulmicort Respules (budesonide inhalation suspension) to Apotex. The lawsuit follows Apotex’s indication of intent

Mr Sweeney has been founder and CEO of eight healthcare service companies including Bridge Medical, a provider of bedside barcode scanning for medication administration, and CardioNet, a developer

Avineuro said that the results of the Phase I studies are expected to be available in May 2009. Based on these and other results, Avineuro Pharmaceuticals plans to

Prior to his retirement from Bristol-Myers Squibb (BMS), Dr Smyth led oncology medical affairs in the US, including the US life-cycle development of paclitaxel (Taxol), carboplatin (Paraplatin) and

The assays have been developed by Nuvera and the University of Texas MD Anderson Cancer Center. The Nuvera test portfolio will also be capable of reporting status of